

Applicant: Riccardo Dalla-Favera  
Serial No.: 08/654,482  
Filed: May 28, 1996  
Page 3

--102. (New) A monoclonal antibody of claim 91.--

--103. (New) A monoclonal antibody of claim 92.--

#### REMARKS

Claims 1-101 were pending in the subject application. Applicant has hereinabove canceled claims 1-87, 93-97 and 99-101 without disclaimer or prejudice to applicant's right to pursue the subject matter of these claims at a later date. Applicant has also amended claims 89-92 and 98 and added new claims 102-103. Support for amended claims 89 and 91 may be found in the specification inter alia on page 21, lines 2-4 and Figure 5B. Support for amended claim 92 may be found in the specification inter alia on page 32, lines 10-12 and page 21, lines 2-4. Support for amended claim 98 may be found in the specification inter alia on page 32, lines lines 22-23. Support for new claims 102-103 may be found in the specification inter alia on page 32, lines 23-27 and in previously pending claim 98. Applicant maintains that the amendments are fully supported by the specification and do not raise any issue of new matter. Accordingly, applicant respectfully requests that the Examiner enter the Amendment. Upon entry of the Amendment, claims 88-92 and 98, as amended, and new claims 102-103 will be pending and under examination.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone at the number provided

Applicant: Riccardo Dalla-Favera  
Serial No.: 08/654,482  
Filed: May 28, 1996  
Page 4

below.

John P. White  
Registration No. 28,678  
Attorney for the Applicant  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400